Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RedHill Biopharma nets $23.7mm through FOPO

Executive Summary

RedHill Biopharma Ltd. netted $23.7mm in a public offering of 4.2mm American Depositary Shares (ADSs) at $6 per ADS. (Each ADS represents 10 ordinary shares). The company expects to use the proceeds to fund clinical development programs, including preparations for a second Phase III trial for RHB104 in Crohn’s disease and initiation of a pivotal Phase III study with RHB204 for nontuberculous mycobacteria (NTM) infections (which was granted qualified infectious disease product (QIDP) designation by the FDA in May 2018 for an expedited review process). Some money will also go toward funding commercial operations--including activities related to the potential launch of Phase III Talicia (RHB105; amoxicillin/omeprazole/rifabutin) for H. pylori infection, which also has the QIDP designation, with an NDA filing anticipated in early 2019--and future acquisitions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies